Factor XI Inhibition- Milvexian, Asundexian, and AXIOMATIC

Be part of the knowledge.

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Analysis from the 2022 European Society of Cardiology (ESC) Congress - Integrating Complex Data into Clinical Practice

Factor XI Inhibition- Milvexian, Asundexian, and AXIOMATIC

Minute CME/CE™
ReachMD Healthcare Image
Choose a format
Media formats available:
Take 1 Minute Challenge
1 Minute Challenge Completed
1.00 credits
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
  • Overview

    In this program, expert faculty review and discuss real-world applications of the latest practice-changing data across different therapeutic areas within cardiovascular medicine presented at the European Society of Cardiology 2022 Meeting.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, including academic and community-based cardiologists - both clinical cardiologists and interventional cardiologists, as well as clinicians in critical care, interventional radiology, emergency, hospital, and vascular medicine. It is also designed for nurses, nurse practitioners, physician assistants, pharmacists, and other health care professionals involved in the care of cardiovascular disorders.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    1. Evaluate recent practice-changing data that can be applied to practice and patients
    2. Apply recently presented data into clinical practice to expand treatment options and improve outcomes for patients
    3. Discuss new data on novel agents and therapeutic approaches for patients with application in the community setting

  • Accreditation and Credit Designation Statements

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and TotalCME, Inc. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE) and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Faculty Disclosure of Commercial Relationships

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Manesh R. Patel, MD, chair for this educational event, has received research funding from Astra Zeneca, Bayer, Janssen, Mytonomy, and Procyrion; and has received consulting fees from Bayer, Janssen, and Novartis.

    John H. Alexander, MD, MHS, faculty for this educational event, received research funding from Artivion/CryoLife, Bayer, Bristol-Myers Squibb, CSL Behring, Ferring, U.S. FDA, Humacyte, U.S. NIH, and XaTek; and has received consulting fees from AbbVie, Akros, Artivion/CryoLife, AtriCure, Bayer, Bristol-Myers Squibb, Ferring, GlaxoSmithKline, Janssen, Pfizer, Portola, and Quantum Genomics.

    Justin A. Ezekowitz, MBBCh, MSc, faculty for this educational event, received research funding from Bayer and Merck; and received consulting fees from Bayer & Merck.

    Marat Fudim, MD, MHS, faculty for this educational event, has no relevant financial relationships with ineligible companies.

    Stephen J. Greene, MD, faculty for this educational event, has received research funding from Novartis, Amgen, Cytokinetics, Bristol Myers Squibb, Merck, AstraZeneca, Pfizer, and Sanofi; and has received consulting fees from Amgen, AstraZeneca, Bristol Myers Squibb, Bayer, Cytokinetics, Novartis, Boehringer Ingelheim/ Lilly, Pfizer, Sanofi, Roche Diagnostics, Tricog Health, PharmaIN, Urovant Pharmaceuticals, and Vifor.

    Renato D. Lopes, MD, MHS, PhD, faculty for this educational event, has received research funding from Bristol Myers Squibb, GlaxoSmithKline, Medtronic, and Pfizer; and has received consulting fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Medtronic, Merck, Pfizer, Portola, and Sanofi.

    Jonathan P. Piccini, MD, MHS, FACC, FAHA, FHRS, faculty for this educational event, has received research funding from Grant R01AG074185 from the National Institutes of Aging, Abbott, the American Heart Association, the Association for the Advancement of Medical Instrumentation, Bayer, Boston Scientific, iRhythm, and Philips; and has received consulting fees from Abbott, AbbVie, ARCA biopharma, Bayer, Boston Scientific, Bristol Myers Squibb (Myokardia), Element Science, Itamar Medical, LivaNova, Medtronic, Milestone, ElectroPhysiology Frontiers, ReCor, Sanofi, Philips, and Up-to-Date. 

    Jennifer Rymer, MD, MBA, faculty for this educational event, received research funding from Idorsia, Chiesi, American Heart Association, and Vascular Cures.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    TotalCME, Inc. planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and TotalCME, Inc. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Acknowledgment

    This activity is supported by independent educational grants from Janssen Pharmaceuticals, Inc., administered by Janssen Scientific Affairs, LLC and Merck Sharp & Dohme LLC.

    Jointly provided by Global Learning Collaborative (GLC) and TotalCME, Inc.

  • Fee Statement

    This activity is FREE to all participants.

  • Instructions

    During the period 9/30/2022 through 9/30/2023, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Schedule8 Jun 2023